Biden has nominated Robert Califf to serve as commissioner of the Food and Drug Administration. Califf, currently a senior advisor at Verily, held the same post during the Obama administration. (The Washington Post)
Johnson & Johnson will split into two companies, separating its consumer group from its prescription drug and medical device businesses. The move follows in the footsteps of Pfizer and Merck, both of which have separated their pharma and consumer divisions. (The Wall Street Journal)
Organon has acquired Forendo Pharma for $75 million upfront and $870 million more if it hits certain milestones. Organon’s candidate for endometriotic lesions is entering Phase II trials. (Endpoints News)
GlaxoSmithKline and Vir’s COVID-19 antibody drug was just as effective when given as a shot in the arm as via a standard infusion, the companies said Friday. GSK plans to ask the Food and Drug Administration to approve the new method of injection. (Reuters)
Rectify Pharmaceuticals is hoping to create a new library of drugs to fix ABC transporters in rare diseases. “This isn’t a one-size-fits-all approach, but we’ve developed a very flexible platform to address multiple transporters within the ABC family,” said Rectify founder. (STAT)
